Examination of the peginterferon+ribavirin+proteaseinhibitor combined effect for type 1 high viral load chronic hepatitis C

Examination of the peginterferon+ribavirin+proteaseinhibitor combined effect for type 1 high viral load chronic hepatitis C - Examination of the peginterferon+ribavirin+proteaseinhibitor combined effect for type 1 high viral load chronic hepatitis C

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007485

Enrollment

Registered

2013-01-30

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

Peginterferon Ribavirin Teraprevir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)The patients whom it is judged not to be cirrhosis by liver histopathology, an imaging, a blood test. (2)The patients whom a hepatocellular carcinoma is not found in by imagings. (3)Age at agreement acquisition; the patients 20 years or older.

Exclusion criteria

Exclusion criteria: (1) The patients whom it is judged not to be cirrhosis by liver histopathology, an imaging, a blood test. (2) The patients whom a hepatocellular carcinoma is not found in by imagings. (3) Age at agreement acquisition; the patients 20 years or older. 2) Exclusion criteria (1) It is the patients with a history of hypersensitivity for peginterferon alpha -2 or other interferon preparation. (2) It is the patients with a history of hypersensitivity for biological preparation such as the vaccine. (3) The patients with a history of ribavirin or other nucleosidic analog (acyclovir, ganciclovir, vidarabine) hypersensitivity. (4) A pregnant woman, the woman who may be pregnant or the woman whom we are nursing. (5) The patients with heart disorder (myocardial infarction, heart failure, arrhythmia) having difficulty in control. (6) The patients with haemoglobinopathies (thalassemia, sickle cell anemia). (7) The patients with chronic renal failure or renal dysfunction that is with 50mL/m or less of creatinine clearance. (8) The patients in a severe psychotic state or the patients with the medical history with severe depression, suicidal ideation or suicide attempt. (9) Patients with serious liver dysfunction. (10) Cerebral hemorrhage, the patients with a history of cerebral infarction. (11) The patients with autoimmune hepatitis. (12) The patients receiving the Sho-saiko-to. (14) In addition, the patients who doctor attending intended, and judged that we were inadequate

Design outcomes

Primary

Measure	Time frame
SVRrate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026